The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Considerations for Polymers Used in Ocular Drug Delivery
Open accessAbstract
Purpose: Age-related eye diseases are becoming more prevalent. A notable increase has been seen in the most common causes including glaucoma, age-related macular degeneration (AMD), and cataract. Current clinical treatments vary from tissue replacement with polymers to topical eye drops and intravitreal injections. Research and development efforts have increased using polymers for sustained release to the eye to overcome treatment challenges, showing promise in improving drug release and delivery, patient experience, and treatment compliance. Polymers provide unique properties that allow for specific engineered devices to provide improved treatment options. Recent work has shown the utilization of synthetic and biopolymer derived biomaterials in various forms, with this review containing a focus on polymers Food and Drug Administration (FDA) approved for ocular use. Methods: This provides an overview of some prevalent synthetic polymers and biopolymers used in ocular delivery and their benefits, brief discussion of the various types and synthesis methods used, and administration techniques. Polymers approved by the FDA for different applications in the eye are listed and compared to new polymers being explored in the literature. This article summarizes research findings using polymers for ocular drug delivery from various stages: laboratory, preclinical studies, clinical trials, and currently approved. This review also focuses on some of the challenges to bringing these new innovations to the clinic, including limited selection of approved polymers. Results: Polymers help improve drug delivery by increasing solubility, controlling pharmacokinetics, and extending release. Several polymer classes including synthetic, biopolymer, and combinations were discussed along with the benefits and challenges of each class. The ways both polymer synthesis and processing techniques can influence drug release in the eye were discussed. Conclusion: The use of biomaterials, specifically polymers, is a well-studied field for drug delivery, and polymers have been used as implants in the eye for over 75 years. Promising new ocular drug delivery systems are emerging using polymers an innovative option for treating ocular diseases because of their tunable properties. This review touches on important considerations and challenges of using polymers for sustained ocular drug delivery with the goal translating research to the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 1×
“These hydrophobic polyesters provide tunable in vivo biodegradation based on the monomer ratio incorporated in the polymer, and have seen usage as drug carriers for small molecules, proteins, and genes (40).”
BackgroundFarah, S., Anderson, D. G., & Langer, R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.012 · Cited by 3,443 · cited 1×
“Due to its susceptibility to hydrolysis, PGA has a faster degradation rate compared to PLA, which has an in vivo biodegradation rate of up to 2 years, but biodegradation of both polymers produces non-toxic byproducts (42).”
BackgroundAn Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering
Gentile, P., Chiono, V., Carmagnola, I., & Hatton, P. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033640 · Cited by 1,593
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379 · cited 15×
“Additionally, PCL has shown promise as an intraocular drug delivery vehicle, with recent experimental work focusing on embedding nanoparticles within contact lenses, injectable in situ forming hydrogels, nanoparticle emulsions and suspensions, microparticles, and capsules for treatment of several diseases including gl…”
BackgroundInfluentialMandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481 · cited 8×
“Polymer solutions for these problems include polymer microand nano-particles which, similar to their role in eyedrop formulations, help improve drug residence time near ocular tissue and assist in penetrating the scleral barriers to ocular entry, thereby increasing the drug dose delivered (158, 201, 202).”
BackgroundInfluentialGaballa, S. A., Kompella, U. B., Elgarhy, O., Alqahtani, A. M., Pierscionek, B., Alany, R. G., & Abdelkader, H. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00843-z · Cited by 255
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224 · cited 10×
“By some estimates, as much as 80% of the tear film’s volume can be turned over in a minute when eyedrops are applied to the eye, leading to significant loss of dose volume (200).”
BackgroundInfluentialOcular Drug Delivery to the Retina: Current Innovations and Future Perspectives
Kim, H. M., & Woo, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010108 · Cited by 198
Hyaluronic acid in ocular drug delivery
Zhang, X., Wei, D., Xu, Y., & Zhu, Q. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118006 · Cited by 196 · cited 1×
“Chitosan has even been explored for micellar delivery (166), including delivery of dexamethasone (167), and HA has been conjugated to peptides to enhance solubility through micelles (97).”
BackgroundCannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment
Olsen, T. W., Feng, X., Wabner, K., Conston, S. R., Sierra, D. H., Folden, D. V., Smith, M. E., & Cameron, J. D. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.05.045 · Cited by 171 · cited 1×
“Perhaps because of these significant challenges to safe and accurate delivery, there has been relatively minimal exploration and characterization of the suprachoroidal space, with early studies beginning only in the mid-2000s and testing of suprachoroidal delivery in animal models of ocular disease by the early 2010s…”
BackgroundFunctional chitosan oligosaccharide nanomicelles for topical ocular drug delivery of dexamethasone
Xu, X., Sun, L., Zhou, L., Cheng, Y., & Cao, F. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115356 · Cited by 153
Novel adeno-associated viral vectors for retinal gene therapy.
Vandenberghe, L. H., & Auricchio, A. (2012) · Gene Therapy · doi:10.1038/gt.2011.151 · Cited by 131
Sun, F., Zheng, Z., Lan, J., Li, X., Li, M., Song, K., & Wu, X. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1622608 · Cited by 85
Micelle-nanogel platform for ferulic acid ocular delivery
Grimaudo, M. A., Amato, G., Carbone, C., Diaz-Rodriguez, P., Musumeci, T., Concheiro, A., Alvarez-Lorenzo, C., & Puglisi, G. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118986 · Cited by 63 · cited 1×
“Several stimuli-responsive poloxamers have been evaluated, including PF-127 for topical delivery of a hydrophobic drug to the anterior segment for treatment of allergic conjunctivitis (160), PF-68 for delivery of ferulic acid (161) or enhancing solubility of gatifloxacin in contact lenses (162), and their combination…”
Background
Cited by
Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases
Onugwu, A. L., Nwagwu, C. S., Onugwu, O. S., Echezona, A. C., Agbo, C. P., Ihim, S. A., Emeh, P., Nnamani, P. O., Attama, A. A., & Khutoryanskiy, V. V. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.018 · Cited by 350
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Metadata
- Authors
- Allyn, M. M., Luo, R. H., Hellwarth, E. B., & Swindle-Reilly, K. E.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2022-01-28
- Volume
- 8
- Pages
- 787644-787644
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W4213156772
- Cited by
- 159
- References
- 14
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.